Stimuli-Responsive Nanotherapeutics for Treatment and Diagnosis of Stroke

Pharmaceutics. 2023 Mar 23;15(4):1036. doi: 10.3390/pharmaceutics15041036.

Abstract

Stroke is the second most common medical emergency and constitutes a significant cause of global morbidity. The conventional stroke treatment strategies, including thrombolysis, antiplatelet therapy, endovascular thrombectomy, neuroprotection, neurogenesis, reducing neuroinflammation, oxidative stress, excitotoxicity, hemostatic treatment, do not provide efficient relief to the patients due to lack of appropriate delivery systems, large doses, systemic toxicity. In this context, guiding the nanoparticles toward the ischemic tissues by making them stimuli-responsive can be a turning point in managing stroke. Hence, in this review, we first outline the basics of stroke, including its pathophysiology, factors affecting its development, current treatment therapies, and their limitations. Further, we have discussed stimuli-responsive nanotherapeutics used for diagnosing and treating stroke with challenges ahead for the safe use of nanotherapeutics.

Keywords: ischemic stroke; nanotherapeutics; oxidative stress; reactive oxygen species; stroke; thrombosis.

Publication types

  • Review

Grants and funding

The authors would like to acknowledge the Science and Engineering Research Board (Statutory Body Established through an Act of Parliament: SERB Act 2008), Department of Science and Technology (DST), (#CRG/2021/005402), and Indian Council of Medical Research (ICMR, New Delhi; File Id: 2021-14161) Government of India for funding the research work related to drug, theranostic and gene delivery in Dr. Tekade lab. The authors would also like to acknowledge the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India, for supporting research on cancer, Parkinson’s disease, and diabetes at NIPER-Ahmedabad.